Two patients at MedStar Union Memorial Hospital receive recently FDA-approved Evoque Tricuspid Valve Replacements for severe ...

Transcatheter tricuspid-valve replacement may improve outcomes. New research findings are summarized in a short video.

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Surgical repair or replacement of the tricuspid valve is usually deferred unless cardiac surgery is being done for other purposes, such as repair or replacement of the mitral or aortic valves.

North America to Lead Revenue While Asia Pacific Emerges as the Fastest-Growing Region, Driven by Rising Cardiovascular Cases and Healthcare Investments Global Transcatheter Devices Market Global ...

Press is the UCLA Principal Investigator. Recently, the FDA approved the first ever Transcatheter Tricuspid Valve Replacement (TTVR) device, Evoque. UCLA hopes to offer the Evoque system in the ...

its transcatheter tricuspid heart valve replacement (TTVR) system, in an Early Feasibility Study (EFS) in the US. The TRICURE EFS (NCT06506942), a prospective, multi-center, single arm study ...

Paris, France and Munich, Germany, January 09, 2025 – (“TRiCares”), a company pioneering a minimally-invasive tricuspid valve that flexes with every heartbeat, announces that the first patients have ...